215 related articles for article (PubMed ID: 30261266)
21. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
22. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of
Negi A; Perveen S; Gupta R; Singh PP; Sharma R
J Med Chem; 2024 Feb; 67(4):2264-2286. PubMed ID: 38351709
[TBL] [Abstract][Full Text] [Related]
23. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
[TBL] [Abstract][Full Text] [Related]
24. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
[TBL] [Abstract][Full Text] [Related]
25. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
26. Bedaquiline.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
[No Abstract] [Full Text] [Related]
27. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
[TBL] [Abstract][Full Text] [Related]
28. Delamanid or pretomanid? A Solomonic judgement!
Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
[TBL] [Abstract][Full Text] [Related]
29. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
30. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
31. Delamanid Resistance: Update and Clinical Management.
Nguyen TVA; Anthony RM; Cao TTH; Bañuls AL; Nguyen VAT; Vu DH; Nguyen NV; Alffenaar JC
Clin Infect Dis; 2020 Dec; 71(12):3252-3259. PubMed ID: 32521000
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
[TBL] [Abstract][Full Text] [Related]
33. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K
Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838
[TBL] [Abstract][Full Text] [Related]
34. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
Patel RV; Riyaz SD; Park SW
Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
36. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
38. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
39. TMC207 becomes bedaquiline, a new anti-TB drug.
Palomino JC; Martin A
Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
[TBL] [Abstract][Full Text] [Related]
40. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]